Comparison
AICAR vs MOTS-c
AICAR is fat loss; MOTS-c is mitochondrial & longevity. They are compared here because they are frequently considered against each other, not because they act alike.
On published evidence alone, AICAR is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.
| AICAR | MOTS-c | |
|---|---|---|
| Class | Fat loss | Mitochondrial & longevity |
| Evidence | Clinical trials | Preliminary human |
| Human trials | ~12 | ~3 |
| Half-life | ~30 minutes | ~1-2 hours |
| Reported range | 50-100 mg | 5-10 mg |
| Frequency | Research protocols vary | 2-3x weekly |
| Routes | Subcutaneous, Oral | Subcutaneous, Intramuscular |
| FDA approved | No | No |
| Research use only | Yes | Yes |
| Banned in sport | Yes | No |
| Studied for | Metabolic research, Endurance research, Cardioprotection studies | Metabolic health research, Insulin sensitivity, Exercise capacity research, Longevity |
| Reported side effects | Elevated uric acid, Headache, Nausea, Hypoglycaemia | Injection-site reactions, Transient fatigue, Headache |
AICAR
AICAR is a nucleoside that is phosphorylated intracellularly to ZMP, an AMP analog that allosterically activates AMP-activated protein kinase. AMPK activation shifts cells toward catabolism: increased glucose uptake, fatty acid oxidation and mitochondrial biogenesis. Rodent studies showing improved endurance without training drove the exercise-mimetic framing and its early prohibition in sport. Human evidence for body composition effects is weak, and its poor oral bioavailability is a substantial practical limitation.
MOTS-c
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene rather than in nuclear DNA, which makes it unusual among signalling peptides. It regulates the folate-methionine cycle, leading to accumulation of AICAR and consequent AMPK activation, shifting metabolism toward glucose uptake and fatty acid oxidation. Exercise raises endogenous MOTS-c, and levels fall with age, which is the basis of both the exercise-mimetic framing and the longevity interest. Human trial data is limited.
AICAR vs MOTS-c: common questions
What is the difference between AICAR and MOTS-c?
AICAR is fat loss and MOTS-c is mitochondrial & longevity, so they act on different pathways. AICAR: An AMPK activator nicknamed exercise in a pill, and one of the earliest compounds added to WADA banned list as a metabolic modulator. MOTS-c: A mitochondria-encoded peptide that acts as an exercise mimetic through AMPK, and one of the better-characterised mitochondrial-derived peptides.
Which has stronger evidence, AICAR or MOTS-c?
AICAR has the stronger evidence base (clinical trials, about 12 human studies) compared with MOTS-c (preliminary human).
Are AICAR and MOTS-c FDA approved?
Neither is FDA approved for any indication.
References
Regulatory and primary sources
- PubChem compound record (CID 65110) ↗ · structure, identifiers, synonyms
- WADA Prohibited List ↗ · current year
- FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
- CAS Registry Number 2627-69-2 ↗ · chemical identity
- PubChem compound record (CID 146675088) ↗ · structure, identifiers, synonyms
Published literature
- AMPK: The energy sensor at the crossroads of aging and cancer.Semin Cancer Biol 2024.PubMed 39197808 · doi:10.1016/j.semcancer.2024.08.002
- Autophagy in the physiological endometrium and cancer.Autophagy 2021.PubMed 32401642 · doi:10.1080/15548627.2020.1752548
- Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function.Cell Metab 2016.PubMed 27345423 · doi:10.1016/j.cmet.2016.05.025
- Modulating Mitophagy in Mitochondrial Disease.Curr Med Chem 2018.PubMed 28618992 · doi:10.2174/0929867324666170616101741
- Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators.IUBMB Life 2009.PubMed 18798311 · doi:10.1002/iub.135
- Targeting AMP-activated protein kinase in sepsis.Front Endocrinol (Lausanne) 2024.PubMed 39469575 · doi:10.3389/fendo.2024.1452993
- AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies.Expert Opin Investig Drugs 2010.PubMed 20367195 · doi:10.1517/13543781003703694
- Caloric restriction and exercise "mimetics'': Ready for prime time?.Pharmacol Res 2016.PubMed 26658171 · doi:10.1016/j.phrs.2015.11.009
- MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.Mitochondrion 2023.PubMed 37307934 · doi:10.1016/j.mito.2023.06.002
- MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.Int J Mol Sci 2022.PubMed 36233287 · doi:10.3390/ijms231911991
- MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.J Transl Med 2026.PubMed 42243958 · doi:10.1186/s12967-026-08398-2
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.Free Radic Biol Med 2016.PubMed 27216708 · doi:10.1016/j.freeradbiomed.2016.05.015
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.Front Endocrinol (Lausanne) 2023.PubMed 36761202 · doi:10.3389/fendo.2023.1120533
- Mitochondrial-Derived Peptides Exacerbate Senescence.Rejuvenation Res 2018.PubMed 30058454 · doi:10.1089/rej.2018.2114
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
- Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging (Albany NY) 2022.PubMed 36490309 · doi:10.18632/aging.204423
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.